Table 4.
Assessment of Ro for sitamaquine and desethyl-sitamaquine plasma pharmacokinetic parameters in patients with visceral leishmaniasis, Bihar, India*
| Analyte | Comparison | Point estimate† | 90% CI | CVw% |
|---|---|---|---|---|
| Sitamaquine | Fed day 10:day 1 | 1.35 | (1.12–1.63) | 35.5 |
| Fed day 21:day 1 | 0.82 | (0.66–1.01) | ||
| Fasted day 10:day 1 | 1.38 | (1.16–1.66) | ||
| Fasted day 21:day 1 | 1.08 | (0.89–1.32) | ||
| All patients day 10:day 1 | 1.37 | (1.20–1.56) | ||
| All patients day 21:day 1 | 0.94 | (0.82–1.07) | ||
| Desethyl-sitamaquine | Fed day 10:day 1 | 7.25 | (5.92–8.88) | 38.5 |
| Fed day 21:day 1 | 4.53 | (3.62–5.66) | ||
| Fasted day 10:day 1 | 6.30 | (5.18–7.66) | ||
| Fasted day 21:day 1 | 5.85 | (4.72–7.24) | ||
| All patients day 10:day 1 | 6.75 | (5.87–7.78) | ||
| All patients day 21:day 1 | 5.15 | (4.46–5.93) |
*
CI = confidence interval; CVw% = within-subject coefficient of variation.
†
Point estimate is the ratio of adjusted geometric means between repeat dosing days (days 21 or 10) and single dose day 1.